Lupin Limited — Updates, 21-02-2025: Press Release

Lupin has received the Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset manufacturing facility following an inspection conducted in late January 2025. This development is a positive indication of the facility's compliance with regulatory standards, reinforcing Lupin's commitment to quality and operational excellence. Managing Director Nilesh Gupta expressed satisfaction with this milestone, highlighting its significance in strengthening the company's position as a reputable pharmaceutical manufacturer. This achievement is expected to bolster investor confidence and support Lupin's market standing across multiple therapeutic areas, including respiratory and cardiovascular segments. Watch closely for how this may enhance Lupin's operational efficiency and product offerings in key markets.